Shares of diagnostics company Castle Biosciences Inc. (CSTL) are down more than 70% from their 52-week high of $78.92, recorded last June, and trade around $22.
The company's current portfolio consists of tests for skin cancers, uveal melanoma, Barrett's esophagus and mental health conditions. DecisionDx-Melanoma, DecisionDx-SCC, DecisionDx-UM are some of the test offerings. A couple of research and development programs for tests in other diseases with high clinical needs are also underway.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com